Group 1 - The core point of the article is that Peijia Medical-B (09996.HK) has submitted a CE mark registration application for its GeminiOne transcatheter edge-to-edge repair (TEER) system for treating mitral valve regurgitation, indicating steady progress in its global strategy [1] - The company has a market capitalization of HKD 4.288 billion and ranks 12th in the medical device II industry [1] - The stock has received a buy rating from one investment bank in the last 90 days, with CITIC Securities providing the latest buy rating for Peijia Medical-B [1] Group 2 - HighLife SAS is identified as the European partner for Peijia Medical-B in the CE mark registration process [1] - The article includes a summary of key indicators for Peijia Medical-B, although specific metrics are not detailed in the provided text [1]

Core Viewpoint - The company has received confirmation from the National Medical Products Administration of China regarding the acceptance of its registration application for the GeminiOne transcatheter edge-to-edge repair (TEER) system [1] Group 1: Product Innovation - GeminiOne is an internally developed innovative TEER device featuring a unique sliding groove mechanical structure that maintains a smaller implant size and delivery system while achieving a longer grasping arm length [1] - The device includes innovative features such as an independent leaflet capture function that reduces surgical complexity, an automatic locking mechanism to prevent repeated locking and unlocking during the procedure, and a multi-angle release design that accommodates a wider range of anatomical structures [1]